Pharmaceutical industry – move towards biotechnology

The research-based pharmaceutical industry is one of the key assets of the European economy. For pharmaceutical drugs, the industry is shifting from small molecule technology towards biotechnology. Active Pharmaceutical Ingredients (API) already accounts for half of the market. Existing API plants will be exploited to the maximum, focusing on energy and cost reduction with minor investments. The bigger investments are taking place in state-of-the-art biotech plants.

Staying on top of developments in the pharma market & biopharma market

Profit recovery programs are currently 'hot'. These programs aim to improve energy efficiency, water reduction and water reuse. At the same time, companies are looking to optimize utility systems, reduce waste and increase the use of alternative energy sources.

How can we help your organization?

Bilfinger Tebodin follows the trends in the pharma market and offers specific services. Our experts are specialized in sustaining and improving existing plants, as well as providing capabilities and expertise to design new biotech plants. With over 100 people involved in pharmaceutical projects, Bilfinger Tebodin is considered a key player on the European market, backed up by a sound international network.

The following areas are our expertise:

  • Pharmaceuticals: pharmaceutical plant design, active pharmaceutical ingredients, HP API's, Medicines (Prescribed, Generics, OTC), OSD/OLD, Cosmetics
  • Biopharma: Recombinant Proteins, Vaccines, MAB/ADC's, Blood Products, Hormones, Antibiotics, Personal Medicines
  • Medical Devices: IV Solutions, EN/PN nutrition
  • R&D, cleanroom design and QC Laboratories

Interested in our pharmaceutical engineering solutions or pharma consultancy services? Do not hesitate to get in touch with us.


Aart-Jan Smit

Eduard Khakimov